These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38901011)

  • 1. Meta-analyzing Results From Disproportionality Analysis of Individual Case Safety Reports: A Note of Caution.
    Fusaroli M; Khouri C; Poluzzi E; De Ponti F; Salvo F; Raschi E
    J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):443-444. PubMed ID: 38901011
    [No Abstract]   [Full Text] [Related]  

  • 2. The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement.
    Fusaroli M; Salvo F; Begaud B; AlShammari TM; Bate A; Battini V; Brueckner A; Candore G; Carnovale C; Crisafulli S; Cutroneo PM; Dolladille C; Drici MD; Faillie JL; Goldman A; Hauben M; Herdeiro MT; Mahaux O; Manlik K; Montastruc F; Noguchi Y; Norén GN; Noseda R; Onakpoya IJ; Pariente A; Poluzzi E; Salem M; Sartori D; Trinh NTH; Tuccori M; van Hunsel F; van Puijenbroek E; Raschi E; Khouri C
    Drug Saf; 2024 Jun; 47(6):575-584. PubMed ID: 38713346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration.
    Fusaroli M; Salvo F; Begaud B; AlShammari TM; Bate A; Battini V; Brueckner A; Candore G; Carnovale C; Crisafulli S; Cutroneo PM; Dolladille C; Drici MD; Faillie JL; Goldman A; Hauben M; Herdeiro MT; Mahaux O; Manlik K; Montastruc F; Noguchi Y; Norén GN; Noseda R; Onakpoya IJ; Pariente A; Poluzzi E; Salem M; Sartori D; Trinh NTH; Tuccori M; van Hunsel F; van Puijenbroek E; Raschi E; Khouri C
    Drug Saf; 2024 Jun; 47(6):585-599. PubMed ID: 38713347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases.
    Khouri C; Petit C; Tod M; Lepelley M; Revol B; Roustit M; Cracowski JL
    J Clin Epidemiol; 2021 Jun; 134():14-21. PubMed ID: 33508405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase.
    Sandberg L; Taavola H; Aoki Y; Chandler R; Norén GN
    Drug Saf; 2020 Oct; 43(10):999-1009. PubMed ID: 32564242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases.
    Khouri C; Revol B; Lepelley M; Mouffak A; Bernardeau C; Salvo F; Pariente A; Roustit M; Cracowski JL
    J Clin Epidemiol; 2021 Nov; 139():191-198. PubMed ID: 34329725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study.
    Mouffak A; Lepelley M; Revol B; Bernardeau C; Salvo F; Pariente A; Roustit M; Cracowski JL; Khouri C
    J Clin Epidemiol; 2021 Oct; 138():73-79. PubMed ID: 34186195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploration of statistical shrinkage parameters of disproportionality methods in spontaneous reporting system of China.
    Wang J; Ye XF; Guo XJ; Zhu TT; Qi N; Hou YF; Zhang TY; Shi WT; Wei X; Liu YZ; Wu GZ; He J
    Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):962-70. PubMed ID: 26095121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of time-to-onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands.
    Scholl JH; van Puijenbroek EP
    Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1361-1367. PubMed ID: 27686554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. vigiRank for statistical signal detection in pharmacovigilance: First results from prospective real-world use.
    Caster O; Sandberg L; Bergvall T; Watson S; Norén GN
    Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):1006-1010. PubMed ID: 28653790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database.
    Renoud L; Khouri C; Revol B; Lepelley M; Perez J; Roustit M; Cracowski JL
    JAMA Intern Med; 2021 Sep; 181(9):1243-1245. PubMed ID: 33904857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.
    Motola D; Piccinni C; Biagi C; Raschi E; Marra A; Marchesini G; Poluzzi E
    Drug Saf; 2012 Apr; 35(4):315-23. PubMed ID: 22376166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
    Michel C; Scosyrev E; Petrin M; Schmouder R
    Clin Drug Investig; 2017 May; 37(5):415-422. PubMed ID: 28224371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.
    Caster O; Aoki Y; Gattepaille LM; Grundmark B
    Drug Saf; 2020 May; 43(5):479-487. PubMed ID: 32008183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database.
    Montastruc JL; Sommet A; Bagheri H; Lapeyre-Mestre M
    Br J Clin Pharmacol; 2011 Dec; 72(6):905-8. PubMed ID: 21658092
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database: A subgroup approach to disproportionality analysis.
    Nguyen KD; Tran TN; Nguyen MT; Nguyen HA; Nguyen HA; Vu DH; Nguyen VD; Bagheri H
    J Clin Pharm Ther; 2019 Feb; 44(1):69-77. PubMed ID: 30129156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical methods for the analysis of adverse event data.
    Kieser M
    Pharm Stat; 2016 Jul; 15(4):290-1. PubMed ID: 27324410
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.